Biosimilars: A Brave New World but Uncertain Terrain

Since the late 1990s, cialis drugs made from living cells have led to therapeutic breakthroughs in previously intractable diseases like HER2-positive breast cancer, cutaneous T-cell lymphoma, and even rheumatoid arthritis, but they’ve also led to an exponential rise in healthcare costs.

According to pharmacy benefit managers (PBM), Express Scripts, biologics are used by only 2% of the population but account for 40% of prescription drug spending in the U.S.

Enter biosimilars, a burgeoning pathway for potentially lower-cost alternatives. Biosimilars are chemically similar, but not identical, to their reference product, and must provide the same safety and efficacy of previously approved agents – an enormous investment in manufacturing precision – but matching one complicated macromolecule to another is only part of the story.

Read Full Article Here >>